Literature DB >> 9004982

Long-term stability of diagnosis and symptom dimensions in a systematic sample of patients with onset of schizophrenia in childhood and early adolescence. II: Postnegative distinction and childhood predictors of adult outcome.

M Maziade1, S Bouchard, N Gingras, L Charron, A Cardinal, M A Roy, B Gauthier, G Tremblay, S Côté, C Fournier, P Boutin, M Hamel, C Mérette, M Martinez.   

Abstract

BACKGROUND: The aim of this study was to verify the presence and stability across life of the positive/negative distinction in early-onset schizophrenia (EO-SZ) through a longitudinal factor analysis of the schizophrenic dimensions, and to identify the factors predicting several indices of long-term outcome for EO-SZ.
METHOD: Forty children consecutively referred for DSM-III-R schizophrenia (SZ) in a specific catchment area comprised the sample.
RESULTS: Across a 14.8-year follow-up, longitudinal factor analysis identified two separate factors corresponding to the positive and negative symptom dimensions. We also observed that: the GAS rated over the last three years of adult illness and the severity of negative symptoms during the stabilised interepisode intervals in adulthood were the indices of adult outcome that were most easily predicted; and the best childhood predictors of adult outcome were premorbid functioning and severity of positive and negative symptoms during acute episodes.
CONCLUSIONS: The presence of premorbid non-psychotic behaviour disturbances (NPBD) and premorbid developmental problems was not related to severity of outcome, in contrast to the former variables.

Entities:  

Mesh:

Year:  1996        PMID: 9004982     DOI: 10.1192/bjp.169.3.371

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  14 in total

Review 1.  Symptom dimensions in the course of childhood-onset schizophrenia.

Authors:  D Bunk; C Eggers; M Klapal
Journal:  Eur Child Adolesc Psychiatry       Date:  1999       Impact factor: 4.785

Review 2.  Management of schizophrenia in children and adolescents: focus on pharmacotherapy.

Authors:  Gabriele Masi; Francesca Liboni
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

3.  The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up.

Authors:  Nora S Vyas; Michael Hadjulis; Apostolos Vourdas; Patrick Byrne; Sophia Frangou
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-10       Impact factor: 4.785

4.  Symptom dimensions and subgroups in childhood-onset schizophrenia.

Authors:  Kirsten E S Craddock; Xueping Zhou; Siyuan Liu; Peter Gochman; Dwight Dickinson; Judith L Rapoport
Journal:  Schizophr Res       Date:  2017-11-13       Impact factor: 4.939

5.  Ten-year diagnostic consistency of bipolar disorder in a first-admission sample.

Authors:  Camilo J Ruggero; Gabrielle A Carlson; Roman Kotov; Evelyn J Bromet
Journal:  Bipolar Disord       Date:  2010-02       Impact factor: 6.744

Review 6.  Children with schizophrenia: clinical picture and pharmacological treatment.

Authors:  Gabriele Masi; Maria Mucci; Cinzia Pari
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  The Maudsley early onset schizophrenia study: cognitive function over a 4-year follow-up period.

Authors:  Sophia Frangou; Michael Hadjulis; Apostolos Vourdas
Journal:  Schizophr Bull       Date:  2007-11-15       Impact factor: 9.306

8.  Use of the ADOS and ADI-R in children with psychosis: importance of clinical judgment.

Authors:  Judith A Reaven; Susan L Hepburn; Randal G Ross
Journal:  Clin Child Psychol Psychiatry       Date:  2008-01       Impact factor: 2.544

9.  Psychosis in children: diagnosis and treatment.

Authors:  H Courvoisie; M J Labellarte; M A Riddle
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

10.  Association between symptom dimensions and categorical diagnoses of psychosis: a cross-sectional and longitudinal investigation.

Authors:  Manuela Russo; Stephen Z Levine; Arsime Demjaha; Marta Di Forti; Stefania Bonaccorso; Paul Fearon; Paola Dazzan; Carmine M Pariante; Anthony S David; Craig Morgan; Robin M Murray; Abraham Reichenberg
Journal:  Schizophr Bull       Date:  2013-05-09       Impact factor: 7.348

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.